- Conditions
- Abdominal Injuries, Physical Abuse, Accidental Fall, Motor Vehicle Injury
- Interventions
- Contrast-Enhanced Ultrasound using Lumason
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 7 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 56
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Developmental Dysplasia of the Hip
- Interventions
- Intraoperative contrast-enhanced ultrasound (CEUS), Lumason
- Diagnostic Test · Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Months to 24 Months
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematoma
- Interventions
- CEUS or Contrast enhanced Ultrasound
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Mitochondrial Myopathies, Mitochondrial Diseases
- Interventions
- Cardiopulmonary Exercise Testing, pGz Bed, Gentle Jogger, Exercise Pedal, Lumason® contrast agent
- Diagnostic Test · Device · Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue
- Interventions
- NaviFUS System, Lumason, Bevacizumab
- Device · Drug
- Lead sponsor
- NaviFUS Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y)
- Drug · Device · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
- Device · Drug · Other + 2 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Necrotizing Enterocolitis of Newborn, Bowel Ischemic
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 18 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypoxic-Ischemic Encephalopathy, Brain Ischemia Hypoxia
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Minute to 18 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma, Mismatch Repair Deficiency
- Interventions
- Pembrolizumab, Navifus Focused Ultrasound Sonification
- Drug · Device
- Lead sponsor
- Jennifer Leddon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Abdominal Injury
- Interventions
- Lumason
- Drug
- Lead sponsor
- David Mooney
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Palo Alto, California • Indianapolis, Indiana + 5 more
- Conditions
- Solid Tumor
- Interventions
- Doppler ultrasound, Long Ensemble Angular-coherence Doppler [LEAD] ultrasound, Contrast-enhanced ultrasound (CEUS)
- Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Echo and myocardial contrast echocardiography perfusion imaging
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Kidney Cancer
- Interventions
- Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Crohn Disease
- Interventions
- Sulfur Hexafluoride, Ultrasound Elastography, Ultrasound Vascularity, Magnetic Resonance Enterography (MRE)
- Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Vesico-Ureteral Reflux
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Months to 35 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Malignant Tumor
- Interventions
- Contrast enhanced ultrasound with Lumason
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Breast Cancer, Contrast Enhanced Ultrasound
- Interventions
- Lumason
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Liver Neoplasms
- Interventions
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization, Medical Chart Review
- Drug · Procedure · Other
- Lead sponsor
- john eisenbrey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Transplantation
- Interventions
- Lumason Contrast-Enhanced Ultrasound
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Crohn Disease
- Interventions
- Ultrasound Microbubble Contrast Agent, Ultrasound Imaging
- Drug · Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Tetralogy of Fallot, Pulmonary Insufficiency
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Appendicitis Acute
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Trauma Abdomen
- Interventions
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON], contrast-enhanced ultrasound
- Drug · Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania